Sung, H. et al. World Most cancers Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Nations. Ca. Most cancers J. Clin. 71, 209–249 (2021).
Worldwide most cancers statistics. Most cancers Analysis UK https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer (2015).
Frankel, R. I. Centennial of Röntgen’s discovery of x-rays. West. J. Med. 164, 497–501 (1996).
Steinberg, F. M. & Raso, J. Biotech prescribed drugs and biotherapy: an outline. J. Pharm. Pharm. Sci. 1, 48–59 (1998).
Commissioner, O. of the. Drug Therapeutics & Regulation within the U.S. FDA https://www.fda.gov/about-fda/fda-history-exhibits/drug-therapeutics-regulation-us (2023).
Grillo-López, A. J. et al. Rituximab: the primary monoclonal antibody authorized for the remedy of lymphoma. Curr. Pharm. Biotechnol. 1, 1–9 (2000).
Swain, S. M., Shastry, M. & Hamilton, E. Concentrating on HER2-positive breast most cancers: advances and future instructions. Nat. Rev. Drug Discov. 22, 101–126 (2023).
Solar, X. et al. Imatinib induces ferroptosis in gastrointestinal stromal tumors by selling STUB1-mediated GPX4 ubiquitination. Cell Demise Dis. 14, 839 (2023).
Solar, C., Gao, W., Liu, J., Cheng, H. & Hao, J. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung most cancers. Respir. Res. 21, 210 (2020).
Carter, J. & Tadi, P. Erlotinib. in StatPearls (StatPearls Publishing, Treasure Island (FL), 2024).
Tewari, Okay. S. et al. Bevacizumab for superior cervical most cancers: remaining total survival and adversarial occasion evaluation of a randomised, managed, open-label, part 3 trial (Gynecologic Oncology Group 240). Lancet 390, 1654–1663 (2017).
Hietanen, E., Koivu, M. Okay. A. & Susi, P. Cytolytic properties and genome evaluation of Rigvir® Oncolytic Virotherapy virus and different Echovirus 7 Isolates. Viruses 14, 525 (2022).
Solar, H. et al. TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is concerned in sorafenib resistance in RCC. Cell Demise Dis. 13, 450 (2022).
Myers, R. M. et al. Humanized CD19-Focused Chimeric Antigen Receptor (CAR) T cells in CAR-Naive and CAR-exposed kids and younger adults with relapsed or refractory acute lymphoblastic leukemia. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 39, 3044–3055 (2021).
Bouffet, Eric et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 mutations. N. Engl. J. Med. 389, 1108–1120 (2023).
Carbone David, P. et al. First-line Nivolumab in Stage IV or recurrent non–small-cell lung most cancers. N. Engl. J. Med. 376, 2415–2426 (2017).
Harrington, Okay. J. et al. Pembrolizumab with or with out chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: up to date outcomes of the Section III KEYNOTE-048 Examine. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 41, 790–802 (2023).
Joura Elmar, A. et al. A 9-Valent HPV Vaccine in opposition to An infection and Intraepithelial Neoplasia in Ladies. N. Engl. J. Med. 372, 711–723 (2015).
Zhang, T. et al. Talimogene Laherparepvec (T-VEC): A overview of the current advances in most cancers remedy. J. Clin. Med. 12, 1098 (2023).
Todo, T. et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a part 2 trial. Nat. Med. 28, 1630–1639 (2022).
Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371–2381 (2021).
Finn, R. S. et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).
Durante, M., Debus, J. & Loeffler, J. S. Physics and biomedical challenges of most cancers remedy with accelerated heavy ions. Nat. Rev. Phys. 3, 777–790 (2021).
World Anti Tumor Medicine Market Analysis Report 2023. https://www.marketresearch.com/Bosson-Analysis-v4252/World-Anti-Tumor-Medicine-Analysis-34934738/ (2023).
Falzone, L., Salomone, S. & Libra, M. Evolution of most cancers pharmacological remedies on the flip of the third millennium. Entrance. Pharmacol. 9, 1300 (2018).
Lemberg, Okay. M., Gori, S. S., Tsukamoto, T., Rais, R. & Slusher, B. S. Medical growth of metabolic inhibitors for oncology. J. Clin. Make investments. 132, e148550 (2022).
Moreno, C., Muñoz, C., Terol, M. J., Hernández-Rivas, J.-Á. & Villanueva, M. Restoration of the immune operate as a complementary technique to deal with Persistent Lymphocytic Leukemia successfully. J. Exp. Clin. Most cancers Res. 40, 321 (2021).
Sliwoski, G., Kothiwale, S., Meiler, J. & Lowe, E. W. Computational strategies in drug discovery. Pharmacol. Rev. 66, 334–395 (2014).
Benjin, X. & Ling, L. Developments, functions, and prospects of cryo‐electron microscopy. Protein Sci. Publ. Protein Soc. 29, 872–882 (2020).
Tsukamoto, Y. et al. 150-kD oxygen-regulated protein is expressed in human atherosclerotic plaques and permits mononuclear phagocytes to face up to mobile stress on publicity to hypoxia and modified low density lipoprotein. J. Clin. Make investments. 98, 1930–1941 (1996).
Hu, Y. et al. NMR-based strategies for protein evaluation. Anal. Chem. 93, 1866–1879 (2021).
Banerjee, A., Bhakta, S. & Sengupta, J. Integrative approaches in cryogenic electron microscopy: Latest advances in structural biology and future views. iScience 24, 102044 (2021).
Dhakal, A., Gyawali, R., Wang, L. & Cheng, J. A big expert-curated cryo-EM picture dataset for machine studying protein particle choosing. Sci. Information 10, 392 (2023).
Skalidis, I. et al. Cryo-EM and synthetic intelligence visualize endogenous protein neighborhood members. Struct. Lond. Engl. 30, 575–589.e6 (2022).
Al-Azzawi, A., Ouadou, A., Tanner, J. J. & Cheng, J. AutoCryoPicker: An unsupervised studying strategy for absolutely automated single particle choosing in Cryo-EM photographs. BMC Bioinforma. 20, 326 (2019).
Yu, H., Ma, H., Yang, Okay., Zhao, Y. & Jin, Y. DeepEM: Deep Neural Networks Mannequin Restoration by way of EM Facet-Channel Data Leakage. in 2020 IEEE Worldwide Symposium on {Hardware} Oriented Safety and Belief (HOST) 209–218 (2020). https://doi.org/10.1109/HOST45689.2020.9300274.
Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 replace. Pharmacol. Res. 187, 106552 (2023).
Iqbal, N. & Iqbal, N. Imatinib: A breakthrough of focused remedy in most cancers. Chemother. Res. Pract. 2014, 1–9 (2014).
Karnoub, A. E. & Weinberg, R. A. Ras oncogenes: break up personalities. Nat. Rev. Mol. Cell Biol. 9, 517–531 (2008).
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, Okay. M. Okay-Ras(G12C) inhibitors allosterically management GTP affinity and effector interactions. Nature 503, 548–551 (2013).
Jänne, P. A. et al. Adagrasib in Non–Small-Cell Lung Most cancers Harboring a KRASG12C Mutation. N. Engl. J. Med. 387, 120–131 (2022).
Ferdinandos, S. et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N. Engl. J. Med. 384, 2371–2381 (2021).
Araujo, L. H. et al. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung most cancers. BMC Most cancers 21, 193 (2021).
Qiu, J., Chen, Okay., Zhong, C., Zhu, S. & Ma, X. Community-based protein-protein interplay prediction methodology maps perturbations of most cancers interactome. PLOS Genet. 17, e1009869 (2021).
Dang, C. V., Reddy, E. P., Shokat, Okay. M. & Soucek, L. Drugging the ‘undruggable’ most cancers targets. Nat. Rev. Most cancers 17, 502–508 (2017).
Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in most cancers. N. Engl. J. Med. 384, 2382–2393 (2021).
Hansen, A. L., Xiang, X., Yuan, C., Bruschweiler-Li, L. & Brüschweiler, R. Excited-state commentary of lively Okay-Ras reveals differential structural dynamics of wild-type versus oncogenic G12D and G12C mutants. Nat. Struct. Mol. Biol. 30, 1446–1455 (2023).
Prepare dinner, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J. & Haigis, Okay. M. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat. Commun. 12, 1808 (2021).
Lavoie, H., Gagnon, J. & Therrien, M. ERK signalling: a grasp regulator of cell behaviour, life and destiny. Nat. Rev. Mol. Cell Biol. 21, 607–632 (2020).
Analysis, C. for D. E. and. FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC. FDA https://www.fda.gov/medication/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc (2021).
Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour development. Nature 619, 160–166 (2023).
Changeux, J.-P. & Christopoulos, A. Allosteric modulation as a unifying mechanism for receptor operate and regulation. Cell 166, 1084–1102 (2016).
Hughes Timothy, P. et al. Asciminib in Persistent Myeloid Leukemia after ABL Kinase inhibitor failure. N. Engl. J. Med. 381, 2315–2326 (2019).
Larkin, J. et al. Mixed Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N. Engl. J. Med. 371, 1867–1876 (2014).
Chen, Y.-N. P. et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers pushed by receptor tyrosine kinases. Nature 535, 148–152 (2016).
Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611–617 (2015).
Smith, A. R., Pucheault, M., Tae, H. S. & Crews, C. M. Focused intracellular protein degradation induced by a small molecule: en path to chemical proteomics. Bioorg. Med. Chem. Lett. 18, 5904–5908 (2008).
Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M. & Cravatt, B. F. Electrophilic PROTACs that degrade nuclear proteins by partaking DCAF16. Nat. Chem. Biol. 15, 737–746 (2019).
Winter, G. E. et al. Selective goal protein degradation by way of Phthalimide conjugation. Science 348, 1376–1381 (2015).
Han, X. et al. Discovery of extremely potent and environment friendly PROTAC degraders of Androgen Receptor (AR) by using weak binding affinity VHL E3 Ligase ligands. J. Med. Chem. 62, 11218–11231 (2019).
Zhao, Q., Lan, T., Su, S. & Rao, Y. Induction of apoptosis in MDA-MB-231 breast most cancers cells by a PARP1-targeting PROTAC small molecule. Chem. Commun. Camb. Engl. 55, 369–372 (2019).
Hines, J., Lartigue, S., Dong, H., Qian, Y. & Crews, C. M. MDM2-recruiting PROTAC presents superior, synergistic anti-proliferative exercise by way of simultaneous degradation of BRD4 and stabilization of p53. Most cancers Res 79, 251–262 (2019).
Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Display Medical Profit in Males with Metastatic Castration-Resistant Prostate Most cancers | Arvinas. https://ir.arvinas.com/news-releases/news-release-details/arvinas-protacr-protein-degrader-bavdegalutamide-arv-110.
Rathkopf, D. E. et al. First-in-human part 1 research of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in sufferers (pts) with metastatic castration-resistant prostate most cancers (mCRPC). J. Clin. Oncol. 42, 134 (2024).
A Examine of AC176 for the Remedy of Metastatic Castration Resistant Prostate Most cancers – Full Textual content View – ClinicalTrials.gov. https://basic.clinicaltrials.gov/ct2/present/NCT05241613.
A Examine to Assess the Security, Pharmacokinetics, and Anti-Tumor Exercise of Oral HP518 in Sufferers With Metastatic Castration-Resistant Prostate Most cancers – Full Textual content View – ClinicalTrials.gov. https://basic.clinicaltrials.gov/ct2/present/NCT05252364.
Petrylak, D. P. et al. A part 2 growth research of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate most cancers (mCRPC). J. Clin. Oncol. 41, TPS290 (2023).
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Display Encouraging Medical Profit Fee in Sufferers with Regionally Superior or Metastatic ER+/HER2- Breast Most cancers | Pfizer. https://www.pfizer.com/information/press-release/press-release-detail/arvinas-and-pfizer-announce-protacr-protein-degrader-arv.
Lloyd, M. R., Wander, S. A., Hamilton, E., Razavi, P. & Bardia, A. Subsequent-generation selective estrogen receptor degraders and different novel endocrine therapies for administration of metastatic hormone receptor-positive breast most cancers: present and rising position. Ther. Adv. Med. Oncol. 14, 17588359221113694 (2022).
Mato, A. R. et al. NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-targeted protein degrader, in sufferers with relapsed or refractory power Lymphocytic Leukemia and B-cell malignancies. Blood 140, 2329–2332 (2022).
Robbins, D. W. et al. Nx-5948, a selective degrader of BTK with exercise in preclinical fashions of hematologic and mind malignancies. Blood 138, 2251 (2021).
Wang, H. et al. P1219: BGB-16673, A BTK degrader, overcomes on-target resistance from btk inhibitors and presents sustainable long-term tumor regression in Lymphoma Xenograft Fashions. HemaSphere 7, e24358c2 (2023).
Li, J. et al. Summary CT128: Section 1 research of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in sufferers with relapsed or refractory B-cell malignancies. Most cancers Res 83, CT128 (2023).
Khan, S. et al. A selective BCL-XL PROTAC degrader achieves protected and potent antitumor exercise. Nat. Med. 25, 1938–1947 (2019).
Examine of Oral MRT-2359 in Chosen Most cancers Sufferers – Full Textual content View – ClinicalTrials.gov. https://basic.clinicaltrials.gov/ct2/present/NCT05546268.
Salarius Prescribed drugs, LLC. A Section 1, Open-Label, Multicenter, First-in-Human Examine to Consider the Security, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SP-3164 in Sufferers With Relapsed/Refractory Non-Hodgkin’s Lymphoma. https://clinicaltrials.gov/research/NCT05979857 (2023).
Ikena Oncology. A First-in-Human (FiH) Examine of IK-595, an Oral Twin MEK/RAF Inhibitor, in Sufferers With RAS-or RAF-Altered Superior Stable Tumors. https://clinicaltrials.gov/research/NCT06270082 (2024).
Gao, J., Li, H.-R., Jin, C., Jiang, J.-H. & Ding, J.-Y. Methods to beat acquired resistance to EGFR TKI within the remedy of non-small cell lung most cancers. Clin. Transl. Oncol. Publ. Fed. Span. Oncol. Soc. Natl Most cancers Inst. Mex. 21, 1287–1301 (2019).
Vecchio, I., Tornali, C., Bragazzi, N. L. & Martini, M. The Discovery of Insulin: An essential milestone within the historical past of medication. Entrance. Endocrinol. 9, 613 (2018).
Bruce Merrifield. Stable Section Synthesis, Nobel Lecture. (1984).
Li, J. & Zhu, Z. Analysis and growth of subsequent technology of antibody-based therapeutics. Acta Pharmacol. Sin. 31, 1198–1207 (2010).
Akbarian, M., Khani, A., Eghbalpour, S. & Uversky, V. N. Bioactive peptides: synthesis, sources, functions, and proposed mechanisms of motion. Int. J. Mol. Sci. 23, 1445 (2022).
Jiang, L. et al. 111In-labeled cystine-knot peptides based mostly on the Agouti-related protein for concentrating on tumor angiogenesis. J. Biomed. Biotechnol. 2012, 368075 (2012).
Breeman, W. A. P. et al. Radiolabelling DOTA-peptides with 68Ga. Eur. J. Nucl. Med. Mol. Imaging 32, 478–485 (2005).
Liu, Z. et al. Two 90Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin focused radionuclide remedy. Mol. Pharm. 8, 591–599 (2011).
Hofman, M. S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in sufferers with metastatic castration-resistant prostate most cancers (TheraP): a randomised, open-label, part 2 trial. Lancet Lond. Engl. 397, 797–804 (2021).
Lei, Z. et al. Novel peptide GX1 inhibits angiogenesis by particularly binding to transglutaminase-2 within the tumorous endothelial cells of gastric most cancers. Cell Demise Dis. 9, 579 (2018).
Chen, Okay. et al. Analysis of 64Cu labeled GX1: a phage show peptide probe for PET imaging of tumor vasculature. Mol. Imaging Biol. 14, 96–105 (2012).
Jiang, J. et al. Noninvasive analysis of PD-L1 expression utilizing Copper 64 labeled peptide WL12 by micro-PET imaging in Chinese language hamster ovary cell tumor mannequin. Bioorg. Med. Chem. Lett. 40, 127901 (2021).
Dolgin, E. Radioactive medication emerge from the shadows to storm the market. Nat. Biotechnol. 36, 1125–1127 (2018).
Guha, M. Amgen swallows Onyx entire. Nat. Biotechnol. 31, 859–860 (2013).
Kaisary, A. V., Tyrrell, C. J., Peeling, W. B. & Griffiths, Okay. Comparability of LHRH Analogue (Zoladex) with Orchiectomy in sufferers with metastatic prostatic carcinoma. Br. J. Urol. 67, 502–508 (1991).
Lamers, C. Overcoming the shortcomings of peptide-based therapeutics. Future Drug Discov. 4, FDD75 (2022).
Keating, G. M. Rituximab: A overview of its use in power lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse massive B-Cell lymphoma. Medicine 70, 1445–1476 (2010).
Lu, R.-M. et al. Growth of therapeutic antibodies for the remedy of ailments. J. Biomed. Sci. 27, 1 (2020).
Swain, S. M. et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-positive metastatic breast most cancers. N. Engl. J. Med. 372, 724–734 (2015).
Van Cutsem, E. et al. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Remedy for Metastatic Colorectal Most cancers: Up to date Evaluation of Total Survival In response to Tumor KRAS and BRAF Mutation Standing. J. Clin. Oncol. 29, 2011–2019 (2011).
Rugo, H. S. et al. Margetuximab Versus Trastuzumab in sufferers with beforehand handled HER2-Constructive Superior Breast Most cancers (SOPHIA): Ultimate total survival outcomes from a randomized Section 3 trial. J. Clin. Oncol. 41, 198–205 (2023).
Cortés, J. et al. Pertuzumab Monotherapy after Trastuzumab-based remedy and subsequent reintroduction of Trastuzumab: Exercise and tolerability in sufferers with superior human epidermal development issue Receptor 2–constructive breast most cancers. J. Clin. Oncol. 30, 1594–1600 (2012).
Goldstein, D. A. et al. First- and second-line Bevacizumab along with chemotherapy for metastatic colorectal most cancers: a america–based mostly cost-effectiveness evaluation. J. Clin. Oncol. 33, 1112–1118 (2015).
Townsend, W. et al. Obinutuzumab Versus Rituximab Immunochemotherapy in beforehand untreated iNHL: Ultimate outcomes from the GALLIUM Examine. HemaSphere 7, e919 (2023).
Warner, J. L. & Arnason, J. E. Alemtuzumab use in relapsed and refractory power lymphocytic leukemia: a historical past and dialogue of future rational use. Ther. Adv. Hematol. 3, 375–389 (2012).
Fisher, J. G. et al. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia 37, 2036–2049 (2023).
Tawbi Hussein, A. et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Superior Melanoma. N. Engl. J. Med. 386, 24–34 (2022).
Mathieu, L. et al. FDA Approval Abstract: Atezolizumab and Durvalumab in Mixture with Platinum‐Based mostly Chemotherapy in Intensive Stage Small Cell Lung Most cancers. Oncologist 26, 433–438 (2021).
McDermott, D., Haanen, J., Chen, T.-T., Lorigan, P. & O’Day, S. Efficacy and security of ipilimumab in metastatic melanoma sufferers surviving greater than 2 years following remedy in a part III trial (MDX010-20). Ann. Oncol. 24, 2694–2698 (2013).
Sangro, B. et al. 4-year total survival replace from the part III HIMALAYA research of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann. Oncol. 35, 448–457 (2024).
Moroney, J. et al. 158P Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor exercise in sufferers with platinum-resistant OVCA. Immuno-Oncol. Technol. 16, (2022).
An Investigational Immunotherapy Examine of BMS-986258 Alone and in Mixture With Nivolumab in Contributors With Stable Cancers That Are Superior or Have Unfold – Full Textual content View – ClinicalTrials.gov. https://basic.clinicaltrials.gov/ct2/present/NCT03446040.
Incyte Company. An Umbrella Examine of INCMGA00012 Alone and in Mixture With Different Therapies in Contributors With Superior or Metastatic Endometrial Most cancers Who Have Progressed on or After Platinum-Based mostly Chemotherapy (POD1UM-204). https://clinicaltrials.gov/research/NCT04463771 (2024).
Jiangsu HengRui Medication Co., Ltd. A Section I, Multicenter, Open-Label Examine of SHR-1702 in Sufferers With Acute Myeloid Leukemia or Myelodysplastic Syndrome. https://clinicaltrials.gov/research/NCT04443751 (2023).
Desai, J. et al. Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, together with tislelizumab, an anti-PD-1 monoclonal antibody, in sufferers with superior strong tumors: A part I/II trial in progress. J. Clin. Oncol. 38, TPS3146 (2020).
Ascierto, P. A. et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), together with nivolumab in pts with melanoma who progressed throughout prior anti–PD-1/PD-L1 remedy (mel prior IO) in all-comer and biomarker-enriched populations. Ann. Oncol. 28, v611–v612 (2017).
Dumbrava, E. et al. 478 COM701 together with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary outcomes of security, tolerability and pharmacokinetics in sufferers with superior strong tumors (NCT04570839). J. Immunother. Most cancers 9, A508–A508 (2021).
Liu, Y. et al. Rising phagocytosis checkpoints in most cancers immunotherapy. Sign Transduct. Goal. Ther. 8, 1–42 (2023).
Li, S. et al. IMM47, a humanized monoclonal antibody that targets CD24, reveals distinctive anti-tumor efficacy by blocking the CD24/Siglec-10 interplay and can be utilized as monotherapy or together with anti-PD1 antibodies for most cancers immunotherapy. Antib. Ther. 6, 240–252 (2023).
DeFrancesco, L. Pheast Therapeutics: One other chunk on the apple. Nat. Biotechnol. https://doi.org/10.1038/d41587-023-00015-7. (2023)
Inc, O. OncoC4 to Current Constructive Information from Ongoing Section 1/2 PRESERVE-001 Trial of ONC-392 in Mixture with pembrolizumab at SITC 2022. GlobeNewswire Information Room https://www.globenewswire.com/news-release/2022/11/07/2549654/0/en/OncoC4-to-Current-Constructive-Information-from-Ongoing-Section-1-2-PRESERVE-001-Trial-of-ONC-392-in-Mixture-with-pembrolizumab-at-SITC-2022.html (2022).
Chames, P., Van Regenmortel, M., Weiss, E. & Baty, D. Therapeutic antibodies: successes, limitations and hopes for the longer term. Br. J. Pharmacol. 157, 220–233 (2009).
Rodríguez-Nava, C. et al. Mechanisms of motion and limitations of monoclonal antibodies and Single Chain Fragment Variable (scFv) within the remedy of most cancers. Biomedicines 11, 1610 (2023).
Value, T. J. et al. Panitumumab versus cetuximab in sufferers with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal most cancers (ASPECCT): a randomised, multicentre, open-label, non-inferiority part 3 research. Lancet Oncol. 15, 569–579 (2014).
Lou, H. & Cao, X. Antibody variable area engineering for bettering most cancers immunotherapy. Most cancers Commun. Lond. Engl. 42, 804–827 (2022).
Shimazaki, Okay. et al. Diabodies concentrating on epithelial membrane protein 2 scale back tumorigenicity of human endometrial most cancers cell strains. Clin. Most cancers Res. J. Am. Assoc. Most cancers Res. 14, 7367–7377 (2008).
Holliger, P. & Hudson, P. J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23, 1126–1136 (2005).
Alderson, R. F. et al. Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug remedy (ADEPT). Bioconjug. Chem. 17, 410–418 (2006).
Peters, C. & Brown, S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep. 35, e00225 (2015).
De Taeye, S. W. et al. FcγR binding and ADCC Exercise of human IgG Allotypes. Entrance. Immunol. 11, 740 (2020).
Wang, Z., Li, H., Gou, L., Li, W. & Wang, Y. Antibody–drug conjugates: Latest advances in payloads. Acta Pharm. Sin. B 13, 4025–4059 (2023).
Takegawa, N. et al. DS-8201a, a brand new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric most cancers T-DM1 resistance. Int. J. Most cancers 141, 1682–1689 (2017).
axispharm. Antibody-drug conjugates(ADCs) listing Permitted by FDA(2000-2023). AxisPharm https://axispharm.com/antibody-drug-conjugatesadcs-list-approved-by-fda2000-2022/ (2022).
Jin, Y., Schladetsch, M. A., Huang, X., Balunas, M. J. & Wiemer, A. J. Stepping ahead in antibody-drug conjugate growth. Pharmacol. Ther. 229, 107917 (2022).
Baah, S., Legal guidelines, M. & Rahman, Okay. M. Antibody–drug conjugates—a tutorial overview. Molecules 26, 2943 (2021).
Tong, J. T. W., Harris, P. W. R., Brimble, M. A. & Kavianinia, I. An Perception into FDA authorized antibody-drug conjugates for most cancers remedy. Molecules 26, 5847 (2021).
Ng, G., Spreter, T., Davies, R. & Wickman, G. ZW38, a Novel Azymetric bispecific CD19-directed CD3 T cell engager antibody drug conjugate with managed T cell activation and improved B cell cytotoxicity. Blood 128, 1841 (2016).
Andreev, J. et al. Bispecific antibodies and Antibody–Drug Conjugates (ADCs) bridging HER2 and Prolactin Receptor enhance efficacy of HER2 ADCs. Mol. Most cancers Ther. 16, 681–693 (2017).
Sellmann, C. et al. Balancing selectivity and efficacy of bispecific Epidermal Progress Issue Receptor (EGFR) × c-MET antibodies and antibody-drug conjugates. J. Biol. Chem. 291, 25106–25119 (2016).
Sadiki, A. et al. Website-specific conjugation of native antibody. Antib. Ther. 3, 271–284 (2020).
Samantasinghar, A. et al. A complete overview of key elements affecting the efficacy of antibody drug conjugate. Biomed. Pharmacother. 161, 114408 (2023).
Amani, N., Dorkoosh, F. A. & Mobedi, H. ADCs, as novel revolutionary weapons for offering a step ahead in focused remedy of malignancies. Curr. Drug Deliv. 17, 23–51 (2020).
Tarantino, P., Ricciuti, B., Pradhan, S. M. & Tolaney, S. M. Optimizing the protection of antibody–drug conjugates for sufferers with strong tumours. Nat. Rev. Clin. Oncol. 20, 558–576 (2023).
Sterner, R. C. & Sterner, R. M. CAR-T cell remedy: present limitations and potential methods. Blood Most cancers J. 11, 69 (2021).
Tokarew, N., Ogonek, J., Endres, S., Von Bergwelt-Baildon, M. & Kobold, S. Instructing an outdated canine new tips: next-generation CAR T cells. Br. J. Most cancers 120, 26–37 (2019).
Larson, R. C. & Maus, M. V. Latest advances and discoveries within the mechanisms and features of CAR T cells. Nat. Rev. Most cancers 21, 145–161 (2021).
Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227–242 (2013).
Hirabayashi, Okay. et al. Twin-targeting CAR-T cells with optimum co-stimulation and metabolic health improve antitumor exercise and stop escape in strong tumors. Nat. Most cancers 2, 904–918 (2021).
Munshi, N. C. et al. Idecabtagene Vicleucel in Relapsed and Refractory A number of Myeloma. N. Engl. J. Med. 384, 705–716 (2021).
Cronk, R. J., Zurko, J. & Shah, N. N. Bispecific chimeric antigen receptor T cell remedy for B cell malignancies and a number of myeloma. Cancers 12, 2523 (2020).
Spiegel, J. Y. et al. CAR T cells with twin concentrating on of CD19 and CD22 in grownup sufferers with recurrent or refractory B cell malignancies: a part 1 trial. Nat. Med. 27, 1419–1431 (2021).
Gardner, R. A. et al. Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 exercise. J. Clin. Oncol. 38, 3035 (2020).
Chen, X. et al. CD19/BCMA dual-targeting Fastcar-T GC012F for sufferers with relapsed/refractory B-cell non-Hodgkin’s Lymphoma: An replace. Blood 142, 6847 (2023).
Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a part 1 dose escalation and growth trial. Nat. Med. 26, 1569–1575 (2020).
Dai, H. et al. Bispecific CAR-T cells concentrating on each CD19 and CD22 for remedy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J. Hematol. Oncol. J. Hematol. Oncol. 13, 30 (2020).
Tong, C. et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood 136, 1632–1644 (2020).
Kotch, C., Barrett, D. & Teachey, D. T. Tocilizumab for the remedy of chimeric antigen receptor T cell-induced cytokine launch syndrome. Knowledgeable Rev. Clin. Immunol. 15, 813–822 (2019).
Bajwa, A. Okay. et al. Efficacy of Siltuximab for chimeric antigen receptor T-cell remedy toxicities – a multicenter retrospective evaluation. Blood 142, 4502 (2023).
Maude, S. L. et al. Tisagenlecleucel in kids and younger adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
Fitzgerald, J. C. et al. Cytokine launch syndrome after chimeric antigen receptor T cell remedy for acute lymphoblastic leukemia. Crit. Care Med. 45, e124–e131 (2017).
Jaeger, U. et al. Portia: A Section 1b research evaluating security and efficacy of Tisagenlecleucel and Pembrolizumab in sufferers with relapsed/refractory diffuse massive B-cell lymphoma. Blood 134, 5325 (2019).
Choy, E. H. et al. Translating IL-6 biology into efficient remedies. Nat. Rev. Rheumatol. 16, 335–345 (2020).
Hamilton, J. A. GM-CSF in irritation. J. Exp. Med. 217, e20190945 (2020).
Lee, Okay. M., Achuthan, A. A. & Hamilton, J. A. GM-CSF: A promising goal in irritation and autoimmunity. ImmunoTargets Ther. 9, 225–240 (2020).
Martinez, M. & Moon, E. Okay. CAR T cells for strong tumors: new methods for locating, infiltrating, and surviving within the tumor microenvironment. Entrance. Immunol. 10, 128 (2019).
Xie, C. et al. A part I research of GPC3 focused CAR-T cell remedy in superior GPC3-expressing hepatocellular carcinoma (HCC). J. Clin. Oncol 41, TPS624 (2023).
Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: part 1 trial interim outcomes. Nat. Med. 28, 1189–1198 (2022).
Kankeu Fonkoua, L. A., Sirpilla, O., Sakemura, R., Siegler, E. L. & Kenderian, S. S. CAR T cell remedy and the tumor microenvironment: Present challenges and alternatives. Mol. Ther. – Oncolytics 25, 69–77 (2022).
Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Mixture immunotherapy with CAR T cells and checkpoint blockade for the remedy of strong tumors. Most cancers Cell 36, 471–482 (2019).
Kuryk, L. et al. Novel insights into mesothelioma remedy: rising avenues and future prospects. Entrance. Oncol. 12, 916839 (2022).
Caruana, I. et al. Heparanase promotes tumor infiltration and antitumor exercise of CAR-redirected T lymphocytes. Nat. Med. 21, 524–529 (2015).
Atsavapranee, E. S., Billingsley, M. M. & Mitchell, M. J. Supply applied sciences for T cell gene enhancing: Purposes in most cancers immunotherapy. EBioMedicine 67, 103354 (2021).
Kamali, E., Rahbarizadeh, F., Hojati, Z. & Frödin, M. CRISPR/Cas9-mediated knockout of clinically related alloantigenes in human main T cells. BMC Biotechnol. 21, 9 (2021).
Sackett, S. D. et al. Genetic engineering of immune evasive stem cell-derived islets. Transpl. Int. 35, 10817 (2022).
Rosenberg, S. A. et al. Use of tumor-infiltrating Lymphocytes and Interleukin-2 within the immunotherapy of sufferers with metastatic melanoma. N. Engl. J. Med. 319, 1676–1680 (1988).
Khawar, M. B. & Solar, H. CAR-NK cells: From pure foundation to design for kill. Entrance. Immunol. 12, 707542 (2021).
Du, N., Guo, F., Wang, Y. & Cui, J. NK cell remedy: a rising star in most cancers remedy. Cancers 13, 4129 (2021).
Xie, G. et al. CAR-NK cells: A promising mobile immunotherapy for most cancers. EBioMedicine 59, 102975 (2020).
Chen, X., Jiang, L. & Liu, X. Pure killer cells: the subsequent wave in most cancers immunotherapy. Entrance. Immunol. 13, 954804 (2022).
Pang, Z., Wang, Z., Li, F., Feng, C. & Mu, X. Present progress of CAR-NK remedy in most cancers remedy. Cancers 14, 4318 (2022).
Marin, D. et al. Security, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a part 1/2 trial. Nat. Med. 30, 772–784 (2024).
Heipertz, E. L. et al. Present views on “Off-The-Shelf” allogeneic NK and CAR-NK cell therapies. Entrance. Immunol. 12, 732135 (2021).
Tang, Y., Zhang, A. X. J., Chen, G., Wu, Y. & Gu, W. Prognostic and therapeutic TILs of cervical most cancers—Present advances and future views. Mol. Ther. – Oncolytics 22, 410–430 (2021).
Dafni, U. et al. Efficacy of adoptive remedy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in superior cutaneous melanoma: a scientific overview and meta-analysis. Ann. Oncol. 30, 1902–1913 (2019).
Chandran, S. S. et al. Remedy of metastatic uveal melanoma with adoptive switch of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, part 2 research. Lancet Oncol. 18, 792–802 (2017).
Sarnaik, A. A. et al. Lifileucel, a tumor-infiltrating lymphocyte remedy, in metastatic melanoma. J. Clin. Oncol. 39, 2656–2666 (2021).
Rohaan, M. W. et al. Tumor-Infiltrating Lymphocyte Remedy or Ipilimumab in Superior Melanoma. N. Engl. J. Med. 387, 2113–2125 (2022).
Alberts, B. Molecular Biology of the Cell. (Garland science, 2017).
Shah, Okay., Al-Haidari, A., Solar, J. & Kazi, J. U. T cell receptor (TCR) signaling in well being and illness. Sign Transduct. Goal. Ther. 6, 412 (2021).
Baulu, E., Gardet, C., Chuvin, N. & Depil, S. TCR-engineered T cell remedy in strong tumors: State-of-the-art and views. Sci. Adv. 9, eadf3700 (2023).
D’Angelo, S. P. et al. SPEARHEAD-1: A part 2 trial of afamitresgene autoleucel (Previously ADP-A2M4) in sufferers with superior synovial sarcoma or myxoid/spherical cell liposarcoma. J. Clin. Oncol. 39, 11504 (2021).
Nagarsheth, N. B. et al. TCR-engineered T cells concentrating on E7 for sufferers with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419–425 (2021).
Sloas, C., Gill, S. & Klichinsky, M. Engineered CAR-Macrophages as Adoptive Immunotherapies for Stable Tumors. Entrance. Immunol. 12, 783305 (2021).
Klichinsky, M. et al. Human chimeric antigen receptor macrophages for most cancers immunotherapy. Nat. Biotechnol. 38, 947–953 (2020).
Cheng, Okay. et al. Tumor‐related macrophages in liver most cancers: From mechanisms to remedy. Most cancers Commun. 42, 1112–1140 (2022).
Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102–116 (2024).
Zhang, L. et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell features. J. Hematol. Oncol. J. Hematol. Oncol. 13, 153 (2020).
Wang, X. et al. Metabolic Reprogramming by way of ACOD1 depletion enhances operate of human induced pluripotent stem cell-derived CAR-macrophages in strong tumors. Nat. Commun. 14, 5778 (2023).
Xue, D. et al. Induced pluripotent stem cell-derived engineered T cells, pure killer cells, macrophages, and dendritic cells in immunotherapy. Developments Biotechnol. 41, 907–922 (2023).
Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D. & Bloom, F. E. Reversal of Diabetes Insipidus in Brattleboro Rats: Intrahypothalamic Injection of Vasopressin mRNA. Science 255, 996–998 (1992).
Annunziata, C. M. et al. Feasibility and preliminary security and efficacy of first-in-human intraperitoneal supply of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian most cancers and malignant peritoneal mesothelioma. J. Clin. Oncol. 38, 3014 (2020).
Reiss, Okay. A. et al. A part 1, first-in-human (FIH) research of the anti-HER2 CAR macrophage CT-0508 in topics with HER2 overexpressing strong tumors. J. Clin. Oncol. 40, 2533 (2022).
Kang, D. D., Li, H. & Dong, Y. Developments of in vitro transcribed mRNA (IVT mRNA) to allow translation into the clinics. Adv. Drug Deliv. Rev. 199, 114961 (2023).
Miller, J. C. et al. Enhancing gene enhancing specificity by attenuating DNA cleavage kinetics. Nat. Biotechnol. 37, 945–952 (2019).
Mangeot, P. E. et al. Genome enhancing in main cells and in vivo utilizing viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins. Nat. Commun. 10, 45 (2019).
Chen, W. C. W. et al. An artificial transcription platform for programmable gene expression in mammalian cells. Nat. Commun. 13, 6167 (2022).
Lundin, J. I. & Checkoway, H. Endotoxin and most cancers. Environ. Well being Perspect. 117, 1344–1350 (2009).
Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering methods to beat the present roadblocks in CAR T cell remedy. Nat. Rev. Clin. Oncol. 17, 147–167 (2020).
Morgan, M. A., Lange, L. & Schambach, A. Prime time for base enhancing within the mitochondria. Sign Transduct. Goal. Ther. 7, 213 (2022).
Kim, Y. G., Cha, J. & Chandrasegaran, S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage area. Proc. Natl Acad. Sci. USA 93, 1156–1160 (1996).
Ichikawa, D. M. et al. A common deep-learning mannequin for zinc finger design permits transcription issue reprogramming. Nat. Biotechnol. 41, 1117–1129 (2023).
Paschon, D. E. et al. Diversifying the construction of zinc finger nucleases for high-precision genome enhancing. Nat. Commun. 10, 1133 (2019).
Kaina, B. A genome-wide screening for DNA restore genes: far more gamers than hitherto recognized. Sign Transduct. Goal. Ther. 5, 204 (2020).
Ding, W. et al. Zinc finger nucleases concentrating on the human papillomavirus E7 oncogene induce E7 disruption and a reworked phenotype in HPV16/18-positive cervical most cancers cells. Clin. Most cancers Res. J. Am. Assoc. Most cancers Res. 20, 6495–6503 (2014).
Ma, D. Security Examine of Zinc Finger Nucleases ZFN-602 and ZFN-758 in HPV-Contaminated Topics. https://clinicaltrials.gov/research/NCT02800369 (2017).
Wang, J. et al. Extremely environment friendly homology-driven genome enhancing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor supply. Nucleic Acids Res. 44, e30 (2016).
Joung, J. Okay. & Sander, J. D. TALENs: a broadly relevant know-how for focused genome enhancing. Nat. Rev. Mol. Cell Biol. 14, 49–55 (2013).
Baker, M. Gene-editing nucleases. Nat. Strategies 9, 23–26 (2012).
Mock, U. et al. Novel lentiviral vectors with mutated reverse transcriptase for mRNA supply of TALE nucleases. Sci. Rep. 4, 6409 (2014).
Holkers, M. et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene switch into human cells. Nucleic Acids Res. 41, e63 (2013).
Qasim, W. et al. Molecular remission of toddler B-ALL after infusion of common TALEN gene-edited CAR T cells. Sci. Transl. Med. 9, eaaj2013 (2017).
Ma, D. Security Examine of Transcription Activator-like Effector Nucleases T512 in HPV16-Contaminated Topics. https://clinicaltrials.gov/research/NCT03226470 (2021).
She, X. et al. Immune surveillance of mind metastatic most cancers cells is mediated by IFITM1. EMBO J. 42, e111112 (2023).
Dong, M. B. et al. Systematic Immunotherapy goal discovery utilizing genome-scale in vivo CRISPR screens in CD8 T cells. Cell 178, 1189–1204.e23 (2019).
Chiu, D. Okay.-C. et al. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response by way of TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. Gastroenterology 159, 609–623 (2020).
Chen, Z. et al. In vivo CD8+ T cell CRISPR screening reveals management by Fli1 in an infection and most cancers. Cell 184, 1262–1280.e22 (2021).
Hu, Y. et al. Security and efficacy of CRISPR-based non-viral PD1 locus particularly built-in anti-CD19 CAR-T cells in sufferers with relapsed or refractory Non-Hodgkin’s lymphoma: a first-in-human part I research. EClinicalMedicine 60, 102010 (2023).
Shakiba, M. et al. TCR sign power defines distinct mechanisms of T cell dysfunction and most cancers evasion. J. Exp. Med. 219, e20201966 (2022).
Zhang, Y. et al. Cyclosporine A-resistant CAR-T cells mediate antitumour immunity within the presence of allogeneic cells. Nat. Commun. 14, 8491 (2023).
Tsujino, T. et al. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate most cancers. Nat. Commun. 14, 252 (2023).
Vojnic, M. et al. Acquired BRAF rearrangements induce secondary resistance to EGFR remedy in EGFR-mutated lung cancers. J. Thorac. Oncol. Publ. Int. Assoc. Examine Lung Most cancers 14, 802–815 (2019).
Chow, R. D. et al. AAV-mediated direct in vivo CRISPR display screen identifies useful suppressors in glioblastoma. Nat. Neurosci. 20, 1329–1341 (2017).
Ye, L. et al. In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Magnificence hybrid vectors identifies membrane targets for bettering immunotherapy for glioblastoma. Nat. Biotechnol. 37, 1302–1313 (2019).
Dervovic, D. et al. In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune remedy response in lung most cancers. Nat. Commun. 14, 3150 (2023).
Lu, Y. et al. Security and feasibility of CRISPR-edited T cells in sufferers with refractory non-small-cell lung most cancers. Nat. Med. 26, 732–740 (2020).
Deng, L. et al. Figuring out CDC7 as a synergistic goal of chemotherapy in resistant small-cell lung most cancers by way of CRISPR/Cas9 screening. Cell Demise Discov. 9, 1–10 (2023).
Wei, L. et al. Genome-wide CRISPR/Cas9 library screening recognized PHGDH as a important driver for Sorafenib resistance in HCC. Nat. Commun. 10, 4681 (2019).
Li, L. et al. In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma. Cell Demise Discov. 9, 1–11 (2023).
Benichou, E. et al. The transcription issue ChREBP Orchestrates liver carcinogenesis by coordinating the PI3K/AKT signaling and most cancers metabolism. Nat. Commun. 15, 1879 (2024).
Porto, E. M., Komor, A. C., Slaymaker, I. M. & Yeo, G. W. Base enhancing: advances and therapeutic alternatives. Nat. Rev. Drug Discov. 19, 839–859 (2020).
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable enhancing of a goal base in genomic DNA with out double-stranded DNA cleavage. Nature 533, 420–424 (2016).
Gaudelli, N. M. et al. Programmable base enhancing of A•T to G•C in genomic DNA with out DNA cleavage. Nature 551, 464–471 (2017).
Rees, H. A. et al. Enhancing the DNA specificity and applicability of base enhancing by way of protein engineering and protein supply. Nat. Commun. 8, 15790 (2017).
Komor, A. C. et al. Improved base excision restore inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with increased effectivity and product purity. Sci. Adv. 3, eaao4774 (2017).
Webber, B. R. et al. Extremely environment friendly multiplex human T cell engineering with out double-strand breaks utilizing Cas9 base editors. Nat. Commun. 10, 5222 (2019).
Sayed, S. et al. Environment friendly correction of oncogenic KRAS and TP53 mutations by way of CRISPR base enhancing. Most cancers Res 82, 3002–3015 (2022).
Anzalone, A. V. et al. Search-and-replace genome enhancing with out double-strand breaks or donor DNA. Nature 576, 149–157 (2019).
Chen, P. J. & Liu, D. R. Prime enhancing for exact and extremely versatile genome manipulation. Nat. Rev. Genet. 24, 161–177 (2023).
Zhao, Z., Shang, P., Mohanraju, P. & Geijsen, N. Prime enhancing: advances and therapeutic functions. Developments Biotechnol. 41, 1000–1012 (2023).
Chen, P. J. et al. Enhanced prime enhancing techniques by manipulating mobile determinants of enhancing outcomes. Cell 184, 5635–5652.e29 (2021).
Fiumara, M. et al. Genotoxic results of base and prime enhancing in human hematopoietic stem cells. Nat. Biotechnol. 1–15 https://doi.org/10.1038/s41587-023-01915-4 (2023).
Liu, P. et al. Improved prime editors allow pathogenic allele correction and most cancers modelling in grownup mice. Nat. Commun. 12, 2121 (2021).
Davis, J. R. et al. Environment friendly prime enhancing in mouse mind, liver and coronary heart with twin AAVs. Nat. Biotechnol. 42, 253–264 (2024).
Abuhamad, A. Y. et al. Reverting TP53 Mutation in Breast Most cancers Cells: Prime Modifying Workflow and Technical Issues. Cells 11, 1612 (2022).
Jang, G., Kweon, J. & Kim, Y. CRISPR prime enhancing for unconstrained correction of oncogenic KRAS variants. Commun. Biol. 6, 1–7 (2023).
Pomeroy, E. J. et al. Multiplex prime enhancing and PASSIGE TM for non-viral technology of an allogeneic CAR-T cell product. Blood 142, 4803 (2023).
Zhou, L. & Yao, S. Latest advances in therapeutic CRISPR-Cas9 genome enhancing: mechanisms and functions. Mol. Biomed. 4, 10 (2023).
Ahmadi, S. E. et al. Viral vectors and extracellular vesicles: Innate supply techniques utilized in CRISPR/Cas-mediated most cancers remedy. Most cancers Gene Ther. 30, 936–954 (2023).
Münch, R. C. et al. Off-target-free gene supply by affinity-purified receptor-targeted viral vectors. Nat. Commun. 6, 6246 (2015).
Gene Switch Medical Examine in X-Linked Myotubular Myopathy – Full Textual content View – ClinicalTrials.gov. https://basic.clinicaltrials.gov/ct2/present/NCT03199469.
Morrison, C. Contemporary from the biotech pipeline—2019. Nat. Biotechnol. 38, 126–131 (2020).
George, L. A. et al. Multiyear Issue VIII Expression after AAV gene switch for Hemophilia A. N. Engl. J. Med. 385, 1961–1973 (2021).
Tabebordbar, M. et al. Directed evolution of a household of AAV capsid variants enabling potent muscle-directed gene supply throughout species. Cell 184, 4919–4938.e22 (2021).
Liu, Y. et al. Cryo-electron tomography of NLRP3-activated ASC complexes reveals organelle co-localization. Nat. Commun. 14, 7246 (2023).
Smith, C. C. et al. Various tumour-specific antigens. Nat. Rev. Most cancers 19, 465–478 (2019).
Tam, Y. Y. C., Chen, S. & Cullis, P. R. Advances in Lipid Nanoparticles for siRNA Supply. Pharmaceutics 5, 498–507 (2013).
Kafil, V. & Omidi, Y. Cytotoxic Impacts of Linear and Branched Polyethylenimine Nanostructures in A431 Cells. BioImpacts BI 1, 23–30 (2011).
Rosenblum, D. et al. CRISPR-Cas9 genome enhancing utilizing focused lipid nanoparticles for most cancers remedy. Sci. Adv. 6, eabc9450 (2020).
Zhang, L. et al. Lipid nanoparticle-mediated environment friendly supply of CRISPR/Cas9 for tumor remedy. NPG Asia Mater. 9, e441 (2017).
Li, C. et al. Ionizable lipid-assisted environment friendly hepatic supply of gene enhancing parts for oncotherapy. Bioact. Mater. 9, 590–601 (2022).
Luo, H. et al. Stress-release design for high-capacity and long-time lifespan aqueous zinc-ion batteries. Mater. At the moment Power 21, 100799 (2021).
Wu, Z. et al. CRISPR/Cas9-3NLS/sgHMGA2@PDA nanosystem is the potential environment friendly gene enhancing remedy for gastric most cancers with HMGA2 excessive expression. Entrance. Oncol. 12, 978533 (2022).
Yu, J. et al. Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic most cancers remedy. Nat. Commun. 13, 7903 (2022).
Hanahan, D. Hallmarks of most cancers: New dimensions. Most cancers Discov. 12, 31–46 (2022).
Chiari, R. et al. Two antigens acknowledged by autologous cytolytic T lymphocytes on a melanoma consequence from a single level mutation in a vital housekeeping gene. Most cancers Res 59, 5785–5792 (1999).
Wang, R.-F., Wang, X., Atwood, A. C., Topalian, S. L. & Rosenberg, S. A. Cloning genes encoding MHC Class II-restricted antigens: Mutated CDC27 as a tumor antigen. Science 284, 1351–1354 (1999).
Perumal, D. et al. Mutation-derived Neoantigen-specific T-cell responses in a number of myeloma. Clin. Most cancers Res. 26, 450–464 (2020).
Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer evaluation. Lancet Oncol. 18, 1009–1021 (2017).
Mitelman, F., Johansson, B. & Mertens, F. Fusion genes and rearranged genes as a linear operate of chromosome aberrations in most cancers. Nat. Genet. 36, 331–334 (2004).
Eckhardt, M. et al. A number of Routes To Oncogenesis are promoted by the human Papillomavirus–Host protein community. Most cancers Discov. 8, 1474–1489 (2018).
HEPAVAC Consortium. et al. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Med 11, 28 (2019).
De Mattos-Arruda, L. et al. Neoantigen prediction and computational views in the direction of scientific profit: suggestions from the ESMO Precision Medication Working Group. Ann. Oncol. 31, 978–990 (2020).
O’Donnell, T. J. et al. MHCflurry: Open-source Class I MHC binding affinity prediction. Cell Syst. 7, 129–132.e4 (2018).
Wells, D. Okay. et al. Key parameters of tumor Epitope immunogenicity revealed by way of a consortium strategy enhance neoantigen prediction. Cell 183, 818–834.e13 (2020).
Roudko, V. et al. Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell 183, 1634–1649.e17 (2020).
Tanyi, J. L. et al. Personalised most cancers vaccine successfully mobilizes antitumor T cell immunity in ovarian most cancers. Sci. Transl. Med. 10, eaao5931 (2018).
Schoen, R. E. et al. Randomized, double-blind, placebo-controlled trial of MUC1 peptide vaccine for prevention of recurrent Colorectal Adenoma. Clin. Most cancers Res. 29, 1678–1688 (2023).
Ott, P. A. et al. An immunogenic private neoantigen vaccine for sufferers with melanoma. Nature 547, 217–221 (2017).
Hubbard, J. M. et al. Security and exercise of PolyPEPI1018 mixed with upkeep remedy in metastatic colorectal most cancers: an open-label, multicenter, Section Ib Examine. Clin. Most cancers Res. 28, 2818–2829 (2022).
Hu, Z. et al. Private neoantigen vaccines induce persistent reminiscence T cell responses and epitope spreading in sufferers with melanoma. Nat. Med. 27, 515–525 (2021).
Schuhmacher, J. et al. Vaccination in opposition to RhoC induces long-lasting immune responses in sufferers with prostate most cancers: outcomes from a part I/II scientific trial. J. Immunother. Most cancers 8, e001157 (2020).
Obara, W. et al. A part I/II research of most cancers peptide vaccine S-288310 in sufferers with superior urothelial carcinoma of the bladder. Ann. Oncol. 28, 798–803 (2017).
Lynn, G. M. et al. Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly improve CD8 T-cell immunity to tumor antigens. Nat. Biotechnol. 38, 320–332 (2020).
Ni, Q. et al. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for mixture immunotherapy of colorectal most cancers. Sci. Adv. 6, eaaw6071 (2020).
Sahin, U. et al. Personalised RNA mutanome vaccines mobilize poly-specific therapeutic immunity in opposition to most cancers. Nature 547, 222–226 (2017).
Zhang, H. et al. Supply of mRNA vaccine with a lipid-like materials potentiates antitumor efficacy by way of Toll-like receptor 4 signaling. Proc. Natl Acad. Sci. 118, e2005191118 (2021).
Rojas, L. A. et al. Personalised RNA neoantigen vaccines stimulate T cells in pancreatic most cancers. Nature 618, 144–150 (2023).
Cafri, G. et al. mRNA vaccine–induced neoantigen-specific T cell immunity in sufferers with gastrointestinal most cancers. J. Clin. Make investments. 130, 5976–5988 (2020).
Wang, Z. et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 11, 711–721 (2004).
Tiriveedhi, V. et al. Security and preliminary proof of biologic efficacy of a mammaglobin-A DNA vaccine in sufferers with secure metastatic breast most cancers. Clin. Most cancers Res. 20, 5964–5975 (2014).
Cecil, D. L. et al. Immunization with a Plasmid DNA vaccine encoding the N-Terminus of insulin-like development issue binding Protein-2 in superior ovarian most cancers results in high-level Kind I immune responses. Clin. Most cancers Res. 27, 6405–6412 (2021).
Trimble, C. L. et al. Security, efficacy, and immunogenicity of VGX-3100, a therapeutic artificial DNA vaccine concentrating on human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled part 2b trial. Lancet 386, 2078–2088 (2015).
Steinman, R. M. Choices about dendritic cells: previous, current, and future. Annu. Rev. Immunol. 30, 1–22 (2012).
Carreno, B. M. et al. A dendritic cell vaccine will increase the breadth and variety of melanoma neoantigen-specific T cells. Science 348, 803–808 (2015).
Liau, L. M. et al. Affiliation of autologous Tumor Lysate-loaded dendritic cell vaccination with extension of survival amongst sufferers with newly recognized and recurrent Glioblastoma: A Section 3 potential externally managed cohort trial. JAMA Oncol. 9, 112 (2023).
Mahoney, D. J., Stojdl, D. F. & Laird, G. Virus remedy for most cancers. Sci. Am. 311, 54–59 (2014).
Anderson, B. D., Nakamura, T., Russell, S. J. & Peng, Okay.-W. Excessive CD46 receptor density determines preferential killing of tumor cells by oncolytic measles Virus. Most cancers Res 64, 4919–4926 (2004).
Jayawardena, N., Burga, L. N., Poirier, J. T. & Bostina, M. Virus–receptor interactions: structural insights for oncolytic virus growth. Oncol. Virother. 8, 39–56 (2019).
Gopinath, S. C. B. et al. Evaluation of compounds that intrude with Herpes Simplex Virus–host receptor interactions utilizing floor plasmon resonance. Anal. Chem. 85, 10455–10462 (2013).
Yu, Z. et al. Enhanced Nectin-1 Expression and Herpes oncolytic sensitivity in extremely migratory and invasive carcinoma. Clin. Most cancers Res. 11, 4889–4897 (2005).
Karki, R. et al. ZBP1-dependent inflammatory cell dying, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy throughout coronavirus an infection. Sci. Immunol. 7, eabo6294 (2022).
Gozgit, J. M. et al. PARP7 negatively regulates the sort I interferon response in most cancers cells and its inhibition triggers antitumor immunity. Most cancers Cell 39, 1214–1226.e10 (2021).
Flores, E. B., Aksoy, B. A. & Bartee, E. Preliminary dose of oncolytic myxoma virus applications sturdy antitumor immunity unbiased of in vivo viral replication. J. Immunother. Most cancers 8, e000804 (2020).
Ma, J. et al. Characterization of virus-mediated immunogenic most cancers cell dying and the results for oncolytic virus-based immunotherapy of most cancers. Cell Demise Dis. 11, 48 (2020).
Ye, Okay. et al. An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte remedy by changing tumors to synthetic antigen-presenting cells in situ. Mol. Ther. 30, 3658–3676 (2022).
Bommareddy, P. Okay., Aspromonte, S., Zloza, A., Rabkin, S. D. & Kaufman, H. L. MEK inhibition enhances oncolytic virus immunotherapy by way of elevated tumor cell killing and T cell activation. Sci. Transl. Med. 10, eaau0417 (2018).
Ramelyte, E. et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Most cancers Cell 39, 394–406.e4 (2021).
Andtbacka, R. H. I. et al. Talimogene Laherparepvec improves sturdy response charge in sufferers with superior melanoma. J. Clin. Oncol. 33, 2780–2788 (2015).
Ott, P. A. & Hodi, F. S. Talimogene Laherparepvec for the remedy of superior melanoma. Clin. Most cancers Res. 22, 3127–3131 (2016).
Soliman, H. et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast most cancers: a part 2 trial. Nat. Med. 29, 450–457 (2023).
Harrington, Okay. J. et al. Talimogene Laherparepvec and Pembrolizumab in recurrent or metastatic squamous cell carcinoma of the top and neck (MASTERKEY-232): A multicenter, Section 1b research. Clin. Most cancers Res. 26, 5153–5161 (2020).
Kelly, C. M. et al. Goal response charge amongst sufferers with regionally superior or metastatic sarcoma handled with talimogene laherparepvec together with Pembrolizumab: A Section 2 scientific trial. JAMA Oncol. 6, 402 (2020).
Fueyo, J. et al. Preclinical characterization of the antiglioma exercise of a Tropism-Enhanced Adenovirus Focused to the Retinoblastoma Pathway. JNCI J. Natl Most cancers Inst. 95, 652–660 (2003).
Lang, F. F. et al. Section I Examine of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and immunotherapeutic results in recurrent malignant Glioma. J. Clin. Oncol. 36, 1419–1427 (2018).
Nassiri, F. et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a part 1/2 trial. Nat. Med. 29, 1370–1378 (2023).
Todo, T., Martuza, R. L., Rabkin, S. D. & Johnson, P. A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl Acad. Sci. 98, 6396–6401 (2001).
Todo, T., Ino, Y., Ohtsu, H., Shibahara, J. & Tanaka, M. A part I/II research of triple-mutated oncolytic herpes virus G47∆ in sufferers with progressive glioblastoma. Nat. Commun. 13, 4119 (2022).
Curti, B. D. et al. Intratumoral oncolytic virus V937 plus ipilimumab in sufferers with superior melanoma: the part 1b MITCI research. J. Immunother. Most cancers 10, e005224 (2022).
Mahalingam, D. et al. Pembrolizumab together with the oncolytic virus pelareorep and chemotherapy in sufferers with superior pancreatic Adenocarcinoma: A Section Ib Examine. Clin. Most cancers Res. 26, 71–81 (2020).
Monge, C. et al. Section I/II research of PexaVec together with immune checkpoint inhibition in refractory metastatic colorectal most cancers. J. Immunother. Most cancers 11, e005640 (2023).
Chesney, J. A. et al. Talimogene laherparepvec together with ipilimumab versus ipilimumab alone for superior melanoma: 5-year remaining evaluation of a multicenter, randomized, open-label, part II trial. J. Immunother. Most cancers 11, e006270 (2023).
Schenk, E. L. et al. A randomized double-blind Section II Examine of the Seneca Valley Virus (NTX-010) versus Placebo for sufferers with extensive-stage SCLC (ES SCLC) who have been secure or responding after a minimum of 4 cycles of Platinum-based chemotherapy: North Central Most cancers Remedy Group (Alliance) N0923 Examine. J. Thorac. Oncol. 15, 110–119 (2020).
Ponce, S. et al. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized part 2 research investigating scientific outcomes and the tumor microenvironment. J. Immunother. Most cancers 11, e007552 (2023).
Heo, J. et al. Randomized dose-finding scientific trial of oncolytic immunotherapeutic vaccinia JX-594 in liver most cancers. Nat. Med. 19, 329–336 (2013).
Cavenee, W. Okay. et al. Genetic origin of mutations predisposing to Retinoblastoma. Science 228, 501–503 (1985).
Xiao, B. et al. Crystal construction of the retinoblastoma tumor suppressor protein certain to E2F and the molecular foundation of its regulation. Proc. Natl Acad. Sci. 100, 2363–2368 (2003).
Pascual-Pasto, G. et al. Therapeutic concentrating on of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Sci. Transl. Med. 11, eaat9321 (2019).
Hwang, T.-H. et al. A mechanistic proof-of-concept scientific trial with JX-594, a focused multi-mechanistic oncolytic Poxvirus, in sufferers with metastatic melanoma. Mol. Ther. 19, 1913–1922 (2011).
Zhang, B. et al. Intratumoral OH2, an oncolytic herpes simplex virus 2, in sufferers with superior strong tumors: a multicenter, part I/II scientific trial. J. Immunother. Most cancers 9, e002224 (2021).
Annels, N. E. et al. Section I Trial of an ICAM-1-Focused Immunotherapeutic-Coxsackievirus A21 (CVA21) as an oncolytic agent in opposition to non muscle-invasive bladder most cancers. Clin. Most cancers Res. 25, 5818–5831 (2019).
Fares, J. et al. Neural stem cell supply of an oncolytic adenovirus in newly recognized malignant glioma: a first-in-human, part 1, dose-escalation trial. Lancet Oncol. 22, 1103–1114 (2021).
Ruano, D. et al. First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic Virus Icovir-5 in sufferers with superior tumors. Mol. Ther. 28, 1033–1042 (2020).
Chow, A., Perica, Okay., Klebanoff, C. A. & Wolchok, J. D. Medical implications of T cell exhaustion for most cancers immunotherapy. Nat. Rev. Clin. Oncol. 19, 775–790 (2022).
Coley, W. B. The remedy of inoperable Sarcoma by Bacterial Toxins (the Blended Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc. R. Soc. Med. 3, 1–48 (1910).
Brunschwig, A. The efficacy Of “Coleyʼs Toxin” within the remedy of Sarcoma * An experimental research. Ann. Surg. 109, 109–113 (1939).
Karbach, J. et al. Section I scientific trial of combined bacterial vaccine (Coley’s Toxins) in sufferers with NY-ESO-1 Expressing cancers: immunological results and scientific exercise. Clin. Most cancers Res. 18, 5449–5459 (2012).
Babjuk, M. et al. EAU Tips on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Replace. Eur. Urol. 59, 997–1008 (2011).
Bisiaux, A. et al. Molecular analyte profiling of the early occasions and tissue conditioning following intravesical bacillus calmette-guerin remedy in sufferers with superficial bladder most cancers. J. Urol. 181, 1571–1580 (2009).
Brandau, S. et al. NK cells are important for efficient BCG immunotherapy. Int. J. Most cancers 92, 697–702 (2001).
Stefanini, G. F. et al. Class I and Class II HLA antigen expression by transitional cell carcinoma of the bladder: correlation with T-cell infiltration and BCG remedy. J. Urol. 141, 1449–1453 (1989).
Kawai, T. & Akira, S. Toll-like receptors and their crosstalk with different innate receptors in an infection and immunity. Immunity 34, 637–650 (2011).
Aleynick, M., Svensson-Arvelund, J., Flowers, C. R., Marabelle, A. & Brody, J. D. Pathogen molecular sample receptor agonists: treating most cancers by mimicking an infection. Clin. Most cancers Res. 25, 6283–6294 (2019).
Nooka, A. Okay. et al. Evaluation of security and immunogenicity of PVX-410 vaccine with or with out lenalidomide in sufferers with smoldering a number of myeloma: a nonrandomized scientific trial. JAMA Oncol. 4, e183267 (2018).
Hammerich, L. et al. Systemic scientific tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25, 814–824 (2019).
Melssen, M. M. et al. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC together with incomplete Freund’s adjuvant in melanoma sufferers. J. Immunother. Most cancers 7, 163 (2019).
Bhatia, S. et al. Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in sufferers with Merkel cell carcinoma. Clin. Most cancers Res. 25, 1185–1195 (2019).
Ferris, R. L. et al. Impact of including Motolimod to Commonplace mixture Chemotherapy and Cetuximab remedy of sufferers with squamous cell carcinoma of the top and neck: the Active8 randomized scientific trial. JAMA Oncol. 4, 1583 (2018).
Kjellberg, R. N., Candy, W. H., Preston, W. M. & Koehler, A. M. The Bragg peak of a proton beam in intracranial remedy of tumors. Trans. Am. Neurol. Assoc. 87, 216–218 (1962).
Lomax, A. J. et al. A remedy planning inter-comparison of proton and depth modulated photon radiotherapy. Radiother. Oncol. 51, 257–271 (1999).
Halperin, E. C. Particle remedy and remedy of most cancers. Lancet Oncol. 7, 676–685 (2006).
Slater, J. M. et al. The proton remedy middle at Loma Linda College Medical Heart: Rationale for and outline of its growth. Int. J. Radiat. Oncol. 22, 383–389 (1992).
Schulz-Ertner, D. & Tsujii, H. Particle radiation remedy utilizing proton and heavier ion beams. J. Clin. Oncol. 25, 953–964 (2007).
Eekers, D. B. P. et al. Good thing about particle remedy in re-irradiation of head and neck sufferers. Outcomes of a multicentric in silico ROCOCO trial. Radiother. Oncol. 121, 387–394 (2016).
Waddle, M. R. et al. Survival after proton and photon radiation remedy in sufferers with head and neck cancers: A research of the nationwide most cancers database. Int. J. Radiat. Oncol. 100, 1330 (2018).
Lee, A. et al. Analysis of Proton remedy reirradiation for sufferers with recurrent head and neck squamous cell carcinoma. JAMA Netw. Open 6, e2250607 (2023).
Mizoe, J. et al. Outcomes of carbon ion radiotherapy for head and neck most cancers. Radiother. Oncol. 103, 32–37 (2012).
Schulz-Ertner, D. et al. Outcomes of carbon ion radiotherapy in 152 sufferers. Int. J. Radiat. Oncol. 58, 631–640 (2004).
Chang, J. Y. et al. Proton Beam Radiotherapy and concurrent chemotherapy for unresectable Stage III non–small cell lung most cancers: remaining outcomes of a Section 2 research. JAMA Oncol. 3, e172032 (2017).
Gjyshi, O. et al. Toxicity and survival after intensity-modulated proton remedy versus passive scattering proton remedy for NSCLC. J. Thorac. Oncol. 16, 269–277 (2021).
Liao, Z. et al. Bayesian adaptive randomization trial of passive scattering proton remedy and intensity-modulated photon radiotherapy for regionally superior non–small-cell lung most cancers. J. Clin. Oncol. 36, 1813–1822 (2018).
Karube, M. et al. Single-fraction carbon-ion radiation remedy for sufferers 80 years of age and older with Stage I non-small cell lung most cancers. Int. J. Radiat. Oncol. 95, 542–548 (2016).
Yamamoto, N. et al. A dose escalation scientific trial of single-fraction carbon ion radiotherapy for peripheral Stage I non–small cell lung most cancers. J. Thorac. Oncol. 12, 673–680 (2017).
Goldin, G. H. Depth-modulated radiation remedy, proton remedy, or conformal radiation remedy and morbidity and illness management in localized prostate most cancers. JAMA 307, 1611 (2012).
Moteabbed, M. et al. A potential comparability of the consequences of interfractional variations on proton remedy and depth modulated radiation remedy for prostate most cancers. Int. J. Radiat. Oncol. 95, 444–453 (2016).
Eichkorn, T. et al. Outcomes of a potential randomized trial on long-term effectiveness of protons and carbon ions in prostate most cancers: LEM I and α/β = 2 Gy overestimates the RBE. Radiother. Oncol. 173, 223–230 (2022).
Nomiya, T. et al. A multi-institutional evaluation of potential research of carbon ion radiotherapy for prostate most cancers: A report from the Japan Carbon ion Radiation Oncology Examine Group (J-CROS). Radiother. Oncol. 121, 288–293 (2016).
Ackroyd, R., Kelty, C., Brown, N. & Reed, M. The historical past of Photodetection and Photodynamic remedy. Photochem. Photobiol. 74, 656 (2001).
Pérez-Hernández, M. et al. Dissecting the molecular mechanism of apoptosis throughout photothermal remedy utilizing gold Nanoprisms. ACS Nano 9, 52–61 (2015).
Yamamoto, N., Homma, S., Sery, T. W., Donoso, L. A. & Kenneth Hoober, J. Photodynamic immunopotentiation: in vitro activation of macrophages by remedy of mouse peritoneal cells with haematoporphyrin by-product and light-weight. Eur. J. Most cancers Clin. Oncol. 27, 467–471 (1991).
Agarwal, M. L., Larkin, H. E., Zaidi, S. I., Mukhtar, H. & Oleinick, N. L. Phospholipase activation triggers apoptosis in photosensitized mouse lymphoma cells. Most cancers Res. 53, 5897–5902 (1993).
Gollnick, S. O., Vaughan, L. & Henderson, B. W. Technology of efficient antitumor vaccines utilizing photodynamic remedy. Most cancers Res 62, 1604–1608 (2002).
Rastinehad, A. R. et al. Gold nanoshell-localized photothermal ablation of prostate tumors in a scientific pilot machine research. Proc. Natl Acad. Sci. 116, 18590–18596 (2019).
Fisher, C. et al. Photodynamic remedy for the remedy of vertebral metastases: A Section I scientific trial. Clin. Most cancers Res. 25, 5766–5776 (2019).
Chen, B. & De Witte, P. A. Photodynamic remedy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor mannequin. Most cancers Lett. 150, 111–117 (2000).
Kim, E. J. et al. Efficacy and security of topical Hypericin Photodynamic Remedy for early-stage cutaneous T-cell Lymphoma (Mycosis Fungoides): The FLASH Section 3 randomized scientific trial. JAMA Dermatol. 158, 1031 (2022).
Folkman, J. Angiogenesis. Annu. Rev. Med. 57, 1–18 (2006).
Potente, M., Gerhardt, H. & Carmeliet, P. Fundamental and therapeutic features of angiogenesis. Cell 146, 873–887 (2011).
Apte, R. S., Chen, D. S. & Ferrara, N. VEGF in signaling and illness: past discovery and growth. Cell 176, 1248–1264 (2019).
Dvorak, H. F. How tumors make unhealthy blood vessels and stroma. Am. J. Pathol. 162, 1747–1757 (2003).
Ruch, C., Skiniotis, G., Steinmetz, M. O., Walz, T. & Ballmer-Hofer, Okay. Construction of a VEGF–VEGF receptor advanced decided by electron microscopy. Nat. Struct. Mol. Biol. 14, 249–250 (2007).
Kawasaki, Okay. et al. Ras signaling directs endothelial specification of VEGFR2+ vascular progenitor cells. J. Cell Biol. 181, 131–141 (2008).
Takahashi, T., Ueno, H. & Shibuya, M. VEGF prompts protein kinase C-dependent, however Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in main endothelial cells. Oncogene 18, 2221–2230 (1999).
Ruan, G.-X. & Kazlauskas, A. Axl is important for VEGF-A-dependent activation of PI3K/Akt: VEGF-dependent activation of PI3K/Akt requires Axl. EMBO J. 31, 1692–1703 (2012).
Gabrilovich, D. I. et al. Manufacturing of vascular endothelial development issue by human tumors inhibits the useful maturation of dendritic cells. Nat. Med. 2, 1096–1103 (1996).
Terme, M. et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal most cancers. Most cancers Res 73, 539–549 (2013).
Voron, T. et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 212, 139–148 (2015).
Sini, P. et al. The antitumor and antiangiogenic exercise of vascular endothelial development issue receptor inhibition is potentiated by ErbB1 blockade. Clin. Most cancers Res. 11, 4521–4532 (2005).
Fons, P. et al. Tumor vasculature is regulated by FGF/FGFR signaling‐mediated angiogenesis and bone marrow‐derived cell recruitment: this mechanism is inhibited by SSR128129E, the primary allosteric antagonist of FGFRs. J. Cell. Physiol. 230, 43–51 (2015).
Hurwitz, H. et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Most cancers. N. Engl. J. Med. 350, 2335–2342 (2004).
Ray-Coquard, I. et al. Olaparib plus Bevacizumab as First-Line Upkeep in Ovarian Most cancers. N. Engl. J. Med. 381, 2416–2428 (2019).
Wick, W. et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N. Engl. J. Med. 377, 1954–1963 (2017).
McDermott, D. F. et al. Medical exercise and molecular correlates of response to atezolizumab alone or together with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).
Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in sufferers with beforehand handled superior gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised part 3 trial. Lancet Oncol. 15, 1224–1235 (2014).
Garon, E. B. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line remedy of stage IV non-small-cell lung most cancers after illness development on platinum-based remedy (REVEL): a multicentre, double-blind, randomised part 3 trial. Lancet 384, 665–673 (2014).
Tabernero, J. et al. Ramucirumab versus placebo together with second-line FOLFIRI in sufferers with metastatic colorectal carcinoma that progressed throughout or after first-line remedy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, part 3 research. Lancet Oncol. 16, 499–508 (2015).
Zhu, A. X. et al. Ramucirumab versus placebo as second-line remedy in sufferers with superior hepatocellular carcinoma following first-line remedy with sorafenib (REACH): a randomised, double-blind, multicentre, part 3 trial. Lancet Oncol. 16, 859–870 (2015).
Escudier, B. et al. Sorafenib in superior clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
Llovet, J. M. et al. Sorafenib in superior hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
Brose, M. S. et al. Sorafenib in radioactive iodine-refractory, regionally superior or metastatic differentiated thyroid most cancers: a randomised, double-blind, part 3 trial. Lancet 384, 319–328 (2014).
Li, J. et al. Randomized, double-blind, placebo-controlled Section III trial of Apatinib in sufferers with chemotherapy-refractory superior or metastatic Adenocarcinoma of the abdomen or gastroesophageal junction. J. Clin. Oncol. 34, 1448–1454 (2016).
Kudo, M. et al. Lenvatinib versus sorafenib in first-line remedy of sufferers with unresectable hepatocellular carcinoma: a randomised part 3 non-inferiority trial. Lancet 391, 1163–1173 (2018).
Motzer, R. J. et al. Sunitinib in sufferers with metastatic renal cell carcinoma. JAMA 295, 2516 (2006).
Reck, M. et al. Docetaxel plus nintedanib versus docetaxel plus placebo in sufferers with beforehand handled non-small-cell lung most cancers (LUME-Lung 1): a part 3, double-blind, randomised managed trial. Lancet Oncol. 15, 143–155 (2014).
Zhang, X. et al. Efficacy and Security of Apatinib Plus Vinorelbine in sufferers with wild-type superior non–small cell lung most cancers after second-line remedy failure: a nonrandomized scientific trial. JAMA Netw. Open 3, e201226 (2020).
Lu, S. et al. Randomized, double-blind, placebo-controlled, multicenter Section II Examine of Fruquintinib after two prior Chemotherapy Regimens in Chinese language sufferers with superior nonsquamous non‒small-cell lung most cancers. J. Clin. Oncol. 36, 1207–1217 (2018).
Shackelford, D. B. & Shaw, R. J. The LKB1–AMPK pathway: metabolism and development management in tumour suppression. Nat. Rev. Most cancers 9, 563–575 (2009).
Bonanno, L. et al. LKB1 Expression correlates with elevated survival in sufferers with superior non–small cell lung most cancers handled with chemotherapy and Bevacizumab. Clin. Most cancers Res. 23, 3316–3324 (2017).
Cascone, T. et al. Upregulated stromal EGFR and vascular reworking in mouse xenograft fashions of angiogenesis inhibitor–resistant human lung adenocarcinoma. J. Clin. Make investments. 121, 1313–1328 (2011).
He, H., Liu, L., Morin, E. E., Liu, M. & Schwendeman, A. Survey of scientific translation of most cancers nanomedicines-lessons discovered from successes and failures. Acc. Chem. Res. 52, 2445–2461 (2019).
Zhang, Z. et al. Functionalization and higher-order group of liposomes with DNA nanostructures. Nat. Commun. 14, 5256 (2023).
Wang, W. et al. Resveratrol-Loaded TPGS-Resveratrol-solid lipid nanoparticles for multidrug-resistant remedy of breast most cancers: in vivo and in vitro research. Entrance. Bioeng. Biotechnol. 9, 762489 (2021).
Zheng, G., Zheng, M., Yang, B., Fu, H. & Li, Y. Enhancing breast most cancers remedy utilizing doxorubicin loaded strong lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH delicate lipid and analysis of the nanomedicine in vitro and in vivo. Biomed. Pharmacother. Biomed. Pharmacother. 116, 109006 (2019).
Rayamajhi, S., Nguyen, T. D. T., Marasini, R. & Aryal, S. Macrophage-derived exosome-mimetic hybrid vesicles for tumor focused drug supply. Acta Biomater. 94, 482–494 (2019).
Basti, H. et al. Catechol derivatives-coated Fe3O4 and gamma-Fe2O3 nanoparticles as potential MRI distinction brokers. J. Colloid Interface Sci. 341, 248–254 (2010).
Hwang, C., Choi, M.-H., Kim, H.-E., Jeong, S.-H. & Park, J.-U. Reactive oxygen species-generating hydrogel platform for enhanced antibacterial remedy. NPG Asia Mater. 14, 1–15 (2022).
Wang, Y., Zhang, Q., Wang, B., Li, P. & Liu, P. LiCl remedy induces programmed cell dying of Schwannoma cells by way of AKT- and MTOR-mediated Necroptosis. Neurochem. Res. 42, 2363–2371 (2017).
Hou, L. et al. Hybrid-membrane-decorated Prussian blue for efficient most cancers immunotherapy by way of tumor-associated macrophages polarization and Hypoxia reduction. Adv. Mater. Deerfield Seaside Fla 34, e2200389 (2022).
Wang, N., Liang, H. & Zen, Okay. Molecular mechanisms that affect the macrophage M1–M2 polarization steadiness. Entrance. Immunol. 5, 614 (2014).
Chaudhari, D. et al. Exploring paclitaxel-loaded adenosine-conjugated PEGylated PLGA nanoparticles for concentrating on triple-negative breast most cancers. Drug Deliv. Transl. Res. 13, 1074–1087 (2023).
Lee, C. Okay. et al. Anti-PD-L1 F(ab) conjugated PEG-PLGA nanoparticle enhances immune checkpoint remedy. Nanotheranostics 6, 243–255 (2022).
Chang, C.-S. et al. Anti-cancer impact of fenbendazole-incorporated PLGA nanoparticles in ovarian most cancers. J. Gynecol. Oncol. 34, e58 (2023).
Cruz-Nova, P. et al. Chemo-radiotherapy with 177Lu-PLGA(RGF)-CXCR4L for the focused remedy of colorectal most cancers. Entrance. Med. 10, 1191315 (2023).
Kim, G. T. et al. PLAG co-treatment will increase the anticancer impact of Adriamycin and cyclophosphamide in a triple-negative breast most cancers xenograft mouse mannequin. Biochem. Biophys. Res. Commun. 619, 110–116 (2022).
Dubey, S. Okay. et al. Latest advances of dendrimers as multifunctional nano-carriers to fight breast most cancers. Eur. J. Pharm. Sci. 164, 105890 (2021).
Huynh, Okay.-H. et al. Bioapplications of Nanomaterials. in Nanotechnology for Bioapplications (ed. Jun, B.-H.) 235–255 (Springer, Singapore). https://doi.org/10.1007/978-981-33-6158-4_10 (2021).
Novartis Tafinlar + Mekinist authorized by FDA for pediatric sufferers with BRAF V600E low-grade glioma, the most typical pediatric mind most cancers. Novartis https://www.novartis.com/information/media-releases/novartis-tafinlar-mekinist-approved-fda-pediatric-patients-braf-v600e-low-grade-glioma-most-common-pediatric-brain-cancer.
Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, part 3 GLOW trial. Nat. Med. 29, 2133–2141 (2023).
FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate most cancers. FDA https://www.fda.gov/medication/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate (2023).
Mai, H.-Q. et al. Toripalimab Plus chemotherapy for recurrent or metastatic nasopharyngeal Carcinoma: The JUPITER-02 randomized scientific trial. JAMA 330, 1961–1970 (2023).
Planchard, D. et al. Osimertinib with or with out Chemotherapy in EGFR-mutated superior NSCLC. N. Engl. J. Med. 389, 1935–1948 (2023).
Colombo, Nicoletta et al. Pembrolizumab for persistent, recurrent, or metastatic cervical most cancers. N. Engl. J. Med. 385, 1856–1867 (2021).
Motzer Robert, J. et al. Nivolumab plus Ipilimumab versus Sunitinib in superior renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
Rini Brian, I. et al. Pembrolizumab plus Axitinib versus Sunitinib for superior renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
Motzer Robert, J. et al. Avelumab plus Axitinib versus Sunitinib for superior renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
Choueiri Toni, Okay. et al. Nivolumab plus Cabozantinib versus Sunitinib for superior renal-cell carcinoma. N. Engl. J. Med. 384, 829–841 (2021).
Albiges, L. et al. Pembrolizumab plus lenvatinib as first-line remedy for superior non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, part 2 trial. Lancet Oncol. 24, 881–891 (2023).
Tawbi Hussein, A. et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Superior Melanoma. N. Engl. J. Med. 386, 24–34 (2022).
Zhang, G. et al. GD2 CAR-T cells together with Nivolumab exhibit enhanced antitumor efficacy. Transl. Oncol. 32, 101663 (2023).
Gong, L. et al. Nasopharyngeal carcinoma cells promote regulatory T cell growth and suppressive exercise by way of CD70-CD27 interplay. Nat. Commun. 14, 1912 (2023).
Hashimoto, M. et al. PD-1 mixture remedy with IL-2 modifies CD8+ T cell exhaustion program. Nature 610, 173–181 (2022).
Cataldo Vince, D., Gibbons Don, L., Pérez-Soler, R. & Quintás-Cardama, A. Remedy of non–small-cell lung most cancers with Erlotinib or Gefitinib. N. Engl. J. Med. 364, 947–955 (2011).
Jóri, B. et al. The mixed remedy of Cabozantinib, Crizotinib, and Osimertinib in a lung most cancers affected person with acquired MET amplification and resistance mutations. Curr. Oncol. 30, 8805–8814 (2023).
von Minckwitz, G. et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast most cancers. N. Engl. J. Med. 377, 122–131 (2017).
Spriggs David, R. & Longo Dan, L. PARP inhibitors in ovarian most cancers remedy. N. Engl. J. Med. 375, 2197–2198 (2016).
Turner Nicholas, C. et al. Palbociclib in hormone-receptor–constructive superior breast most cancers. N. Engl. J. Med. 373, 209–219 (2015).
Montesinos, Pau et al. Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia. N. Engl. J. Med. 386, 1519–1531 (2022).
Liu, B. et al. Concentrating on TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates remedy response in hepatocellular carcinoma. J. Exp. Clin. Most cancers Res. 41, 1–19 (2022).
Jiang, Y.-Y. et al. TP63, SOX2, and KLF5 set up a core regulatory circuitry that controls epigenetic and transcription patterns in esophageal squamous cell carcinoma cell strains. Gastroenterology 159, 1311–1327.e19 (2020).
Zheng, C. et al. Donafenib and GSK-J4 synergistically induce ferroptosis in liver most cancers by upregulating HMOX1 Expression. Adv. Sci. Weinh. Baden.-Wurtt. Ger. 10, e2206798 (2023).
Xu, Z. et al. Efficacy and security of lapatinib and trastuzumab for HER2-positive breast most cancers: a scientific overview and meta-analysis of randomised managed trials. BMJ Open 7, e013053 (2017).
Yaeger, R. et al. Adagrasib with or with out Cetuximab in Colorectal Most cancers with Mutated KRAS G12C. N. Engl. J. Med. 388, 44–54 (2023).
Novartis Prescribed drugs. A Randomised, Multi-Centre, Open-Label, Section III Examine of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Mixture in Sufferers With HER2/ErbB2 Constructive Major Breast Most cancers. https://clinicaltrials.gov/research/NCT00490139 (2021).
Socinski, M. A. et al. Atezolizumab for first-line remedy of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018).
Loupakis, F. et al. Preliminary Remedy with FOLFOXIRI and Bevacizumab for metastatic colorectal most cancers. N. Engl. J. Med. 371, 1609–1618 (2014).
Hosaka, Okay. et al. KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas. Proc. Natl Acad. Sci. USA 120, e2303740120 (2023).
Srinivasan, R. et al. Outcomes from a part II research of bevacizumab and erlotinib in topics with superior hereditary leiomyomatosis and renal cell most cancers (HLRCC) or sporadic papillary renal cell most cancers. J. Clin. Oncol. 38, 5004 (2020). 5004.
Prager, G. W. et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Most cancers. N. Engl. J. Med. 388, 1657–1667 (2023).
Friedlander, M. et al. Pamiparib together with tislelizumab in sufferers with superior strong tumours: outcomes from the dose-escalation stage of a multicentre, open-label, part 1a/b trial. Lancet Oncol. 20, 1306–1315 (2019).
Kanjee, Z., Crowe, B. & Rodman, A. Accuracy of a Generative Synthetic Intelligence Mannequin in a Advanced Diagnostic Problem. JAMA 330, 78–80 (2023).
Liberti, M. V. & Locasale, J. W. The Warburg impact: How does it profit most cancers cells? Developments Biochem. Sci. 41, 211 (2016).
Xu, D. et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature 580, 530–535 (2020).
Chen, J., Li, G., Solar, D., Li, H. & Chen, L. Analysis progress of hexokinase 2 in inflammatory-related ailments and its inhibitors. Eur. J. Med. Chem. 264, 115986 (2024).
Fu, Okay. et al. Streptococcus anginosus promotes gastric irritation, atrophy, and tumorigenesis in mice. Cell 187, 882–896.e17 (2024).
Ling, A. L. et al. Medical trial hyperlinks oncolytic immunoactivation to survival in glioblastoma. Nature 623, 157–166 (2023).
Cui, C. et al. OrienX010, an oncolytic virus, in sufferers with unresectable stage IIIC–IV melanoma: a part Ib research. J. Immunother. Most cancers 10, e004307 (2022).
Gállego Pérez-Larraya, J. et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic Pontine Glioma. N. Engl. J. Med. 386, 2471–2481 (2022).
Bazan-Peregrino, M. et al. VCN-01 disrupts pancreatic most cancers stroma and exerts antitumor results. J. Immunother. Most cancers 9, e003254 (2021).
Heo, J. et al. Security and dose escalation of the focused oncolytic adenovirus OBP-301 for refractory superior liver most cancers: Section I scientific trial. Mol. Ther. 31, 2077–2088 (2023).
Shirakawa, Y. et al. Section I dose-escalation research of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal most cancers sufferers unfit for traditional remedies. Eur. J. Most cancers 153, 98–108 (2021).
Nemunaitis, J. et al. A Section I Examine of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for numerous strong tumors. Mol. Ther. 18, 429–434 (2010).
Fakih, M. et al. Security and efficacy of the tumor-selective adenovirus enadenotucirev, together with nivolumab, in sufferers with superior/metastatic epithelial most cancers: a part I scientific trial (SPICE). J. Immunother. Most cancers 11, e006561 (2023).
Garcia-Carbonero, R. et al. Section 1 research of intravenous administration of the chimeric adenovirus enadenotucirev in sufferers present process main tumor resection. J. Immunother. Most cancers 5, 71 (2017).
Machiels, J.-P. et al. A part 1 dose escalation research of the oncolytic adenovirus enadenotucirev, administered intravenously to sufferers with epithelial strong tumors (EVOLVE). J. Immunother. Most cancers 7, 20 (2019).
Dispenzieri, A. et al. Section I trial of systemic administration of Edmonston pressure of measles virus genetically engineered to specific the sodium iodide symporter in sufferers with recurrent or refractory a number of myeloma. Leukemia 31, 2791–2798 (2017).
Packiriswamy, N. et al. Oncolytic measles virus remedy enhances tumor antigen-specific T-cell responses in sufferers with a number of myeloma. Leukemia 34, 3310–3322 (2020).
Galanis, E. et al. Carcinoembryonic antigen-expressing oncolytic measles virus by-product in recurrent glioblastoma: a part 1 trial. Nat. Commun. 15, 493 (2024).
Galanis, E. et al. Section I Trial of Intraperitoneal administration of an oncolytic measles virus pressure engineered to specific carcinoembryonic antigen for recurrent ovarian most cancers. Most cancers Res. 70, 875–882 (2010).
Andtbacka, R. H. I. et al. Medical responses of Oncolytic Coxsackievirus A21 (V937) in sufferers with unresectable melanoma. J. Clin. Oncol. 39, 3829–3838 (2021).
Rudin, C. M. et al. Section 1, open-label, dose-escalation research on the protection, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or with out pembrolizumab, in sufferers with superior strong tumors. J. Immunother. Most cancers 11, e005007 (2023).
Geletneky, Okay. et al. Section I/IIa research of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in sufferers with progressive main or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Most cancers 12, 99 (2012).
Hajda, J. et al. Section 2 trial of oncolytic H-1 Parvovirus remedy exhibits security and indicators of immune system activation in sufferers with metastatic pancreatic ductal Adenocarcinoma. Clin. Most cancers Res. 27, 5546–5556 (2021).
Hajda, J. et al. A non-controlled, single arm, open label, part II research of intravenous and intratumoral administration of ParvOryx in sufferers with metastatic, inoperable pancreatic most cancers: ParvOryx02 protocol. BMC Most cancers 17, 576 (2017).
Desjardins, A. et al. Recurrent Glioblastoma handled with recombinant Poliovirus. N. Engl. J. Med. 379, 150–161 (2018).
Beasley, G. M. et al. Section I trial of intratumoral PVSRIPO in sufferers with unresectable, treatment-refractory melanoma. J. Immunother. Most cancers 9, e002203 (2021).
Beasley, G. M. et al. Multimodality evaluation confers a prognostic advantage of a T-cell infiltrated tumor microenvironment and peripheral immune standing in sufferers with melanoma. J. Immunother. Most cancers 10, e005052 (2022).
Comins, C. et al. REO-10: A Section I research of intravenous Reovirus and Docetaxel in sufferers with superior most cancers. Clin. Most cancers Res. 16, 5564–5572 (2010).
Galanis, E. et al. Section II trial of intravenous administration of Reolysin® (Reovirus Serotype-3-dearing Pressure) in sufferers with metastatic melanoma. Mol. Ther. 20, 1998–2003 (2012).
Noonan, A. M. et al. Randomized Section 2 trial of the oncolytic Virus Pelareorep (Reolysin) in upfront remedy of metastatic pancreatic Adenocarcinoma. Mol. Ther. 24, 1150–1158 (2016).
Sborov, D. W. et al. A Section I trial of single-agent Reolysin in sufferers with relapsed a number of myeloma. Clin. Most cancers Res. 20, 5946–5955 (2014).
Jiffry, J. et al. Oncolytic Reovirus (pelareorep) induces autophagy in KRAS-mutated colorectal most cancers. Clin. Most cancers Res. 27, 865–876 (2021).
Burke, M. J. et al. Section I trial of Seneca Valley Virus (NTX‐010) in kids with relapsed/refractory strong tumors: A report of the Youngsters’s Oncology Group. Pediatr. Blood Most cancers 62, 743–750 (2015).
Toulmonde, M. et al. Randomized part 2 trial of intravenous oncolytic virus JX-594 mixed with low-dose cyclophosphamide in sufferers with superior soft-tissue sarcoma. J. Hematol. Oncol. J. Hematol. Oncol. 15, 149 (2022).
Toulmonde, M. et al. Reshaping the tumor microenvironment of chilly soft-tissue sarcomas with oncolytic viral remedy: a part 2 trial of intratumoral JX-594 mixed with avelumab and low-dose cyclophosphamide. Mol. Most cancers 23, 38 (2024).
